Upcoming research to be presented at the 2013 Breast Cancer Symposium

SAN FRANSISCO, CA – Five additional studies of note are among those that will be presented at the 2013 Breast Cancer Symposium, taking place September 7-9, 2013 at the San Francisco Marriott Marquis in San Francisco, California. Two studies examine cognitive function in women who undergo treatment for early-stage breast cancer; a third evaluates impact of tumor genotyping on clinical trial enrollment; and the final two evaluate the outcomes of different treatment approaches.

Saturday, September 7 Presentations

Abstract #48:Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome.

General Poster Session ASaturday, September 7, 2013, 11:30 AM – 1:00 PM PSTSaturday, September 7, 2013, 4:30 PM – 6:00 PM PSTGolden Gate Hall

Napa Parinyanitikul, MDThe University of Texas MD Anderson Cancer CenterHouston, TX

Abstract # 55:Ten-year outcomes of accelerated partial breast irradiation compared with whole breast irradiation: A matched-pair analysis.

Poster Discussion ASaturday, September 7, 2013, 4:00 PM – 4:20 PM PSTYerba Buena Ballroom, Salon 8

Jessica Wobb, MDOakland University William Beaumont School ofMedicine, Beaumont Cancer InstituteRoyal Oak, MI

Sunday, September 8 Presentations

Abstract # 105:Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.

Poster Discussion BSunday, September 8, 2013, 3:00 PM – 3:20 PM PSTYerba Buena Ballroom, Salon 8

Lara Heflin, PhDNew Mexico Highlands UniversityLas Vegas, NM

Abstract # 104:Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.

Poster Discussion BSunday, September 8, 2013, 3:00 PM – 3:20 PM PSTYerba Buena Ballroom, Salon 8

Hope S. Rugo, MDUCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, CA

Abstract # 145:Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.

Poster Discussion B

Sunday, September 8, 2013, 4:00 PM – 4:20 PM PSTYerba Buena Ballroom, Salon 8

Aditya Bardia, MDMassachusetts General Hospital,Harvard Medical SchoolBoston, MA

Source: American Society of Clinical Oncology